Provided by Tiger Fintech (Singapore) Pte. Ltd.

Phathom Pharmaceuticals

14.56
-0.2900-1.95%
Post-market: 14.560.00000.00%19:10 EST
Volume:971.48K
Turnover:14.30M
Market Cap:1.04B
PE:-3.83
High:15.28
Open:14.45
Low:14.07
Close:14.85
52wk High:16.08
52wk Low:2.21
Shares:71.14M
Float Shares:51.95M
Volume Ratio:1.10
T/O Rate:1.87%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.8010
EPS(LYR):-5.2920
ROE:-3489.00%
ROA:-42.54%
PB:-2.45
PE(LYR):-2.75

Loading ...

Phathom Pharmaceuticals (PHAT): Assessing Valuation After First Patient Dosed in VOQUEZNA EoE Phase 2 Trial

Simply Wall St.
·
Nov 13

Phathom Pharmaceuticals Inc - Topline Results Expected in 2027

THOMSON REUTERS
·
Nov 04

Phathom Pharmaceuticals Announces First Patient Dosed in Phase 2 Study of Voquezna® (Vonoprazan) in Eosinophilic Esophagitis (Eoe)

THOMSON REUTERS
·
Nov 04

Phathom Pharmaceuticals Announces First Patient Dosed in Phase 2 Study of VOQUEZNA® (vonoprazan) in Eosinophilic Esophagitis (EoE)

GlobeNewswire
·
Nov 04

Phathom Pharmaceuticals Inc - Topline Results of Phase 2 Eoe Study Expected in 2027

THOMSON REUTERS
·
Nov 04

Phathom Pharmaceuticals to Present at Jefferies Global Healthcare Conference

Reuters
·
Nov 03

Phathom Pharmaceuticals’ Q3 Earnings: Strong Growth Amid Challenges

TIPRANKS
·
Nov 01

Stock Track | Phathom Pharmaceuticals Soars 8.41% on Strong Q3 Results and Analyst Upgrade

Stock Track
·
Oct 31

Stock Track | Phathom Pharmaceuticals Soars 8.41% on Strong Q3 Results and Analyst Upgrade

Stock Track
·
Oct 31

Stock Track | Phathom Pharmaceuticals Soars 5.79% Pre-market on Strong Q3 Results and Analyst Upgrade

Stock Track
·
Oct 31

Stock Track | Phathom Pharmaceuticals Soars 5.79% Pre-market on Strong Q3 Earnings and Analyst Upgrade

Stock Track
·
Oct 31

Phathom Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Oct 31

Phathom Pharmaceuticals: Strong Q3 Performance and Promising Growth Drive Buy Rating

TIPRANKS
·
Oct 31

Stock Track | Phathom Pharmaceuticals Soars 10.50% Pre-Market on Strong Q3 Results and Raised Guidance

Stock Track
·
Oct 30

Stock Track | Phathom Pharmaceuticals Soars 10.50% on Strong Q3 Results and Raised 2025 Guidance

Stock Track
·
Oct 30

Craig-Hallum Sticks to Its Buy Rating for Phathom Pharmaceuticals (PHAT)

TIPRANKS
·
Oct 30

Stock Track | Phathom Pharmaceuticals Soars 6.43% Pre-market on Strong Q3 Results and Raised Guidance

Stock Track
·
Oct 30

Phathom Q3 revenue up 25%, beats estimates

Reuters
·
Oct 30

Phathom Pharmaceuticals Reports Q3 Net Revenue of $49.5 Million

Reuters
·
Oct 30

BRIEF-Phathom Pharmaceuticals Q3 Net Income USD -30 Million

Reuters
·
Oct 30